Weekly Feature | Nasdaq Dorsey Wright

Weekly Feature

Published: December 22, 2025

This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.

With no changes to any of the Invesco models, we take a look at the Invesco Biotechnology & Genome ETF (PBE).

There are no changes to any of the Invesco models this week. As we discussed in last Thursday’s report, healthcare and biotechnology have recently shown significant improvement. Biotechnology now has an average score of 5.10, while healthcare has an average of 4.56; they also have the two highest score directions out of all 134 groups in the Asset Class Group Scores at 3.93 and 3.20, respectively.

Investors looking to allocate towards this strength may wish to consider the Invesco Biotechnology & Genome ETF (PBE). PBE currently has a strong 5.57 fund score, which is 0.47 points better than the average for all biotechnology funds, and a positive 4.79 score direction. On its default chart, PBE has completed two consecutive buy signals, most recently breaking a spread quadruple top in October that took out resistance that had been in place since August 2024. PBE reached a fresh all-time high last month and now sits one box away from setting a new high watermark, which would come with a double top break at $84. PBE currently sits in heavily overbought territory with a weekly overbought/oversold (OBOS) reading of 74%, so those looking to add exposure may be best served to do so on a pullback or after prices have normalized at current levels. Year-to-date (through 12/19) PBE has gained 24.32% on a price return basis.

Back to report

DISCLOSURE

**Unless otherwise stated, the performance numbers herein are based on price returns and do not include dividends or all transaction costs. Past performance is not indicative of future results. Potential for profits is accompanied by possibility of loss. PowerShares has arranged with Dorsey, Wright to provide this specialized ETF Point & Figure Analysis page on PowerShares sponsored products. The Point & Figure analysis, models and resulting rankings, including any information, data or commentary included herein, are created and provided solely by Dorsey, Wright & Associates. Such analysis, models and rankings should not be considered an offer to purchase or sell, or a solicitation of an offer to buy or purchase any security. The examples presented do not take into consideration commissions, tax implications, or other transactions costs. Neither Dorsey, Wright nor PowerShares through this ETF page provide investment advice or recommendations regarding any security, fund or market. As the investment professional making the final decision with respect to allocations, including any related suitability, fiduciary or other legal obligation, please remember to adhere to all applicable laws, regulations, and rules including NASD Rules 2090 and 2111. The percentage of the portfolio devoted to any ETF is at the sole discretion of the financial advisor or the customer, and not Dorsey, Wright & Associates or PowerShares. If you are not familiar with the Point & Figure methodology, we suggest you read "Point & Figure Charting, 4th Edition" by Thomas J. Dorsey and visit the PnF University, www.dorseywright.com. If you are not familiar with the PowerShares products, or Exchange Traded Funds (ETFs), we suggest you visit www.powershares.com.